Výsledky vyhledávání - "Jinwan, Wang"

Akademický článek

Risk Prediction of Major Adverse Cardiovascular Events Occurrence Within 6 Months After Coronary Revascularization: Machine Learning Study

Autor: Jinwan Wang, Shuai Wang, Mark Xuefang Zhu, Tao Yang, Qingfeng Yin, Ya Hou

Publikováno v: JMIR Medical Informatics, Vol 10, Iss 4, p e33395 (2022)

BackgroundAs a major health hazard, the incidence of coronary heart disease has been increasing year by year. Although coronary revascularization, mainly percutaneous coronary intervention, has played an important role in the treatment of coronary he

Externí odkaz: https://doaj.org/article/16244d6cf5c04ca6bcc6a8f01689663c

Zobrazit plný text záznamu

Akademický článek

Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies

Autor: Xinan Sheng, Jie Jin, Zhisong He, Yiran Huang, Aiping Zhou, Jinwan Wang, Xiubao Ren, Dingwei Ye, Xu Zhang, Shukui Qin, Fangjian Zhou, Binhui Wang, Jun Guo

Publikováno v: BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)

Abstract Background We performed a pooled analysis of the COMPARZ study assessing efficacy and safety of pazopanib versus sunitinib in treatment-naïve Chinese patients with locally advanced and/or metastatic renal cell carcinoma (a/mRCC). Methods In

Externí odkaz: https://doaj.org/article/5a56d159a5834946bca072440889c334

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Machine learning for the prediction of minor amputation in University of Texas grade 3 diabetic foot ulcers.

Autor: Shiqi Wang, Jinwan Wang, Mark Xuefang Zhu, Qian Tan

Publikováno v: PLoS ONE, Vol 17, Iss 12, p e0278445 (2022)

Minor amputations are performed in a large proportion of patients with diabetic foot ulcers (DFU) and early identification of the outcome of minor amputations facilitates medical decision-making and ultimately reduces major amputations and deaths. Ho

Externí odkaz: https://doaj.org/article/715ead08f9fb45268c0ae6cc13d6047c

Zobrazit plný text záznamu

Akademický článek

A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer

Autor: Xiaoyan Si, Jinwan Wang, Ying Cheng, Jianhua Shi, Liying Cui, Helong Zhang, Yunchao Huang, Wei Liu, Lei Chen, Jiang Zhu, Shucai Zhang, Wei Li, Yan Sun, Hanping Wang, Xiaotong Zhang, Mengzhao Wang, Lin Yang, Li Zhang

Publikováno v: Therapeutic Advances in Medical Oncology, Vol 12 (2020)

Background: Carboxyamidotriazole (CAI), a calcium channel blocker, inhibits tumor cell proliferation, metastasis, and angiogenesis. This trial aimed to determine whether CAI combined with conventional chemotherapy could prolong progression-free survi

Externí odkaz: https://doaj.org/article/139061d82c9d427297f29127b1efa5a0

Zobrazit plný text záznamu

Akademický článek

Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial

Autor: Jianhui Ma, Yan Song, Jianzhong Shou, Yuxian Bai, Hanzhong Li, Xiaodong Xie, Hong Luo, Xiubao Ren, Jiyan Liu, Dingwei Ye, Xianzhong Bai, Cheng Fu, Shukui Qin, Jinwan Wang, Ai-Ping Zhou

Publikováno v: Frontiers in Oncology, Vol 10 (2020)

Introduction: Sequential therapy with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) is effective in some patients with metastatic renal cell carcinoma (mRCC) progressed from or were intolerant to a prior TKIs. An

Externí odkaz: https://doaj.org/article/b7cf31287a7b4934860ef32fed34d45d

Zobrazit plný text záznamu

Akademický článek

Gastroenteropancreatic neuroendocrine tumor registry study in China

Autor: Lin Cong, MD, Wenming Wu, MD, Wenhui Lou, MD, Jinwan Wang, MD, Feng Gu, MD, Jiaming Qian, MD, Jianming Xu, MD, Feng Bi, MD, Sanjun Cai, MD, Chengwei Tang, MD, Yulong He, MD, Jie Zhong, MD, Yupei Zhao, MD

Publikováno v: Journal of Pancreatology, Vol 1, Iss 1, Pp 35-38 (2018)

Abstract. Objectives:. The aim of this multicenter, prospective, registry study was to summarize the epidemiology of Chinese patients with locally advanced and end-stage gastroenteropancreatic neuroendocrine tumors (GEP-NETs) as well as the diagnosti

Externí odkaz: https://doaj.org/article/cec9d66413ea4fff9c853600745a8e31

Zobrazit plný text záznamu

Akademický článek

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

Autor: Yongkun Sun, Wei Niu, Feng Du, Chunxia Du, Shuting Li, Jinwan Wang, Li Li, Fengqing Wang, Yu Hao, Chuan Li, Yihebali Chi

Publikováno v: Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-9 (2016)

Abstract Background Anlotinib is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret. We aimed to evaluate the safety, pharmacokinetics, and antitumor activity of anlotin

Externí odkaz: https://doaj.org/article/ba3724af39794da5a26b3aadf84008cc

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání